Biology Department, Barnard College, New York, NY 10027, USA.
Department of Biomedical Sciences, Florida State University College of Medicine, Tallahassee, FL 32306, USA.
Biomolecules. 2021 Oct 29;11(11):1600. doi: 10.3390/biom11111600.
The microsporidia is an obligate intracellular parasite that causes honey bee mortality and contributes to colony collapse. Fumagillin is presently the only pharmacological control for infections in honey bees. Resistance is already emerging, and alternative controls are critically needed. spp. exhibit increased sensitivity to heat shock, a common proteotoxic stress. Thus, we hypothesized that targeting the proteasome, the major protease removing misfolded proteins, might be effective against infections in honey bees. genome analysis and molecular modeling revealed an unexpectedly compact proteasome apparently lacking multiple canonical subunits, but with highly conserved proteolytic active sites expected to be receptive to FDA-approved proteasome inhibitors. Indeed, were strikingly sensitive to pharmacological disruption of proteasome function at doses that were well tolerated by honey bees. Thus, proteasome inhibition is a novel candidate treatment strategy for microsporidia infection in honey bees.
微孢子虫是一种专性细胞内寄生虫,可导致蜜蜂死亡,并导致蜂群衰竭。目前,烟曲霉素是控制蜜蜂感染的唯一药物。但已经出现了耐药性,因此迫切需要替代控制方法。 spp. 对热休克表现出更高的敏感性,热休克是一种常见的蛋白毒性应激。因此,我们假设针对蛋白酶体(主要的蛋白酶,可去除错误折叠的蛋白质)可能是一种有效的治疗方法。 基因组分析和分子建模显示,蛋白酶体出乎意料地紧凑,显然缺乏多个典型亚基,但具有高度保守的蛋白酶活性位点,预计可接受 FDA 批准的蛋白酶体抑制剂。事实上, 对蛋白酶体功能的药物抑制非常敏感,而这种抑制作用的剂量对蜜蜂是耐受的。因此,蛋白酶体抑制是治疗蜜蜂微孢子虫感染的一种新的候选治疗策略。